-
-
Overview
-
Rituximab is a glycosylated monoclonal antibody that binds to the CD20 cell surface protein which is widely expressed on B-cells. Through the binding of rituximab’s Fc portion, the antibody-dependent cellular cytotoxicity pathway (ADCC) and the complement-dependent cytotoxicity (CDC) pathway are initiated, both leading to B-cell lysis (Chisari, 2021). In addition, direct apoptosis can be the result of the inhibition of various B-cell signalling pathways. Rituximab is used in targeted therapy for chronic lymphocytic leukaemia (CLL), non-Hodgkin lymphoma (NHL) and some non-cancer pathologies, such as, multiple sclerosis (Johnson, 2001).
Please contact us at for specific academic pricing.
-
- Properties
- Reference
-
Overview